Cellular and Molecular Effects of Targeting the CBP/β-Catenin Interaction with PRI-724 in Melanoma Cells, Drug-Naïve and Resistant to Inhibitors of BRAF

Anna Gajos-Michniewicz, Michal Wozniak, Katarzyna Anna Kluszczynska, Malgorzata Czyz

Abstract read

In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anna Gajos-MichniewiczDepartment of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.ORCID 0000-0002-6159-4194

Michal WozniakDepartment of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.ORCID 0000-0003-2251-8647

Katarzyna Anna KluszczynskaDepartment of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.ORCID 0000-0002-7290-1647

Malgorzata CzyzDepartment of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.ORCID 0000-0002-8279-4742

Funding

Medical University of Lodz Rector's Research Grant 503/1-156-01/503-99-016National Science Centre (Poland) 2021/05/X/NZ3/00210

6 · The paper itself

Abstract

Targeted therapies, including treatment with inhibitors of BRAF

Indexed as

beta CateninCREB-Binding ProteinDrug Resistance, NeoplasmMelanomaProtein Kinase InhibitorsProto-Oncogene Proteins B-rafApoptosisCell Line, TumorGene Expression Regulation, NeoplasticHumansMAP Kinase Kinase 1MAP Kinase Kinase 2Protein BindingPyridonesPyrimidinonesSurvivinbeta CateninBRAF protein, humanCREB-Binding ProteinMAP2K2 protein, humanMAP Kinase Kinase 1MAP Kinase Kinase 2Protein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonesSurvivintrametinibVemurafenibCBP/β-catenin signalingdrug resistancemelanomaPRI-724survivin

Identifiers

PMID41227355

DOI10.3390/cells14211710

PMCPMC12609419

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.